Background {#Sec1}
==========

Paget's disease, described by Sir James Paget in 1874 \[[@CR1]\], is classified as mammary and extramammary subgroups. Extramammary Paget's disease (EMPD) is a rare condition that is part of a spectrum of intraepithelial adenocarcinomas characterized by proliferation of apocrine cells called Paget cells, located in the basal layer of the skin and often can reach to the entire epithelium thickness \[[@CR2]\]. EMPD incidence age is 50 to 80 with the peak age of incidence being 65 years \[[@CR2]\]. EMPD of the vulva is most common accounting for up to 65% of cases while other areas affected include perianal area, male groin, scrotum, and axillae \[[@CR2]\]. Perianal Paget's disease (PPD) is a subgroup of EMPD, which is an uncommon intraepithelial neoplasm. The true incidence of the disease is difficult to estimate due to its rarity, but it is known to represent less than 1% of all anal diseases and 6.5% of all cases of Paget's disease \[[@CR3]\]. Although its etiology has never been definitively determined, there are two types of PPD, primary likely represents intra-epithelial neoplasm from an apocrine source, whereas secondary disease may represent "pagetoid" spread from an anorectal malignancy \[[@CR4]\].

In Brazil, Tanaka et al. \[[@CR5]\] reported 14 cases of EMPD, four of which involved women with disease in the vulvar, groin or perianal areas. Trindade et al. \[[@CR6]\] reported a primary Brazilian PPD patient, which presented erythematous, itching and little bleeding. The staging tests were normal, without evidence of metastasis.

Imiquimod is an immune response modulating drug that targets toll-like receptors of dendritic and Langerhans cells, which results in the release of multiple cytokines and can directly induce apoptosis of transformed epithelial cells \[[@CR7]\]. Imiquimod is a drug of choice for genital warts, vulvar and vaginal intraepithelial neoplasia, and actinic keratosis \[[@CR8]\], and it has emerged as a promising drug for the treatment of vulvar and scrotal EMPD \[[@CR9]--[@CR11]\]. However, the exact statistics for PPD treatment efficiency with Imiquimod have not been well described.

The aim of this study was to describe a case of PPD in Brazil, and the effectiveness of topical Imiquimod therapy.

Case presentation {#Sec2}
=================

This study was conducted according to the Declaration of Helsinki, and was approved by the local institutional review board guidelines (number: 54306316.4.0000.5514).

The patient, a 66-year-old Brazilian male sought the Coloproctology Division at USF, Bragança Paulista, São Paulo, Brazil due to a complaint of an anal lump for 3 years, and fistula with absolute hyperemia and decreased caliber of the stool accompanied by increased constipation with occasional rectum bleeding. The colonoscopy showed the presence of intense perianal rash with xeroderma, peeling skin, warty lesions and a severe stenosis of the anal orifice (Fig. [1a](#Fig1){ref-type="fig"}). Also, no changes in the rectal mucosa and absence of polyps in the colon were observed.Fig. 1Colonoscopy examination in the perianal Paget's disease (PPD) patient revealed skin condition improvement (**a**) Presence of intense perianal rash with xeroderma, peeling skin, warty lesions and a severe stenosis of the anal orifice. **b-d** After 4, 8 and 12 months treatment using Imiquimod 5% cream, respectively

Perianal surgical biopsies were performed with segments of skin resection and subcutaneous tissue at areas where there was a lack of skin irregularity and hardened consistency. Large biopsies fragments of four quadrants were removed. Post-treatment biopsies were performed using the same technique. Perianal biopsy showed the atypical Paget cells suggesting PPD or balloon cells melanoma (Fig. [2a](#Fig2){ref-type="fig"}). For the differential diagnosis, Melan-A, CDX-2, cytokeratin 20 (CK20), cytokeratin 7 (CK7), p63, and human epidermal growth factor receptor 2 (HER2) immunostaining markers panel was analyzed. Positive staining only for cytokeratin 20 (Fig. [2b](#Fig2){ref-type="fig"}) and CDX-2 (Fig. [2c](#Fig2){ref-type="fig"}) markers was observed. No PPD diagnosis secondary to a colorectal origin was confirmed. The anal orifice stenosis was treated by sphincterotomy.Fig. 2Histologic Findings of a Case of a Perianal Paget's disease (PPD) (**a**) PPD diagnostic was obtained by histological examination showing the presence of Paget cells which are larger than the surrounding keratinocytes and have prominent nuclei and moderate amounts of pale cytoplasm (hematoxylin and eosin stain, original magnification × 200). **b** Positive immunostaining for cytokeratin 20 (CD20) (original magnification × 400). **c** Positive immunostaining for CDX-2 (original magnification × 400)

Local excision is considered the first-line therapy in PPD cases and most of them requiring also an abdominoperineal amputation of the rectum with a permanent colostomy. The patient refused that option. Then, since there was no dermis invasion and no associated colorectal carcinoma, the PPD treatment choice was Imiquimod 5% cream for 12 months. Every 4 months a new colonoscopy revealed skin condition improvement (Fig. [1b-d](#Fig1){ref-type="fig"}) and perianal biopsy showed no residual PPD (data not shown).

After the first Imiquimod treatment cycle, two more surgical biopsies were performed and a new Imiquimod cycle was prescribed. After 3 months a third biopsy revealed no sign of lesion. The patient is currently being closely followed every 3 months. The patient remains without signs of recurrence to date. If no lesion is observed, the follow-up may include biopsy from the old perianal lesion once a year and colonoscopy once every 2 years.

It is interestingly to note that patient has presented pain and irritation of the perianal skin during the period of Imiquimod application and the inflammatory process completely improved after the first 45 days with remaining residual local pruritus.

Conclusions {#Sec3}
===========

PPD is categorized into primary cutaneous origin and secondary due to the extension of a visceral malignancy as anorectal or colon. Grow et al. \[[@CR12]\] reported a 76% association of PPD with adjacent or bowel carcinoma. This study describes a primary cutaneous PPD patient without invasion of the dermis and no associated colorectal carcinoma.

Differential diagnoses of PPD include Bowen's disease, contact dermatitis, lichenoid lesions, psoriasis, melanoma, perianal Crohn's involvement, mycosis fungoides, squamous cell carcinoma and tinea cruris \[[@CR13]\]. Immunostaining markers may enhance the diagnostic accuracy. CDX-2 and CK20 positive markers have been known as markers for colorectal-derived Paget's cells \[[@CR14]--[@CR16]\]. Interestingly, our primary cutaneous PPD patient presented both markers positive and no internal malignancy was identified. CDX-2 sensitivity is modest and it must be analyzed in conjunction with additional immunostaining markers \[[@CR17]\]. The negative CK7 marker was observed in our case. Most of the publications confirm that primary PPD is usually CK7 positive and CK20 negative \[[@CR18], [@CR19]\], whereas EMPD secondary to colorectal carcinoma is positive for CK7 and CK20 \[[@CR18]\].

Melan-2 is the melanocyte differentiation marker, and it is negativity excludes amelanotic melanoma \[[@CR20]\]. Overexpression of HER-2 protein is seen in 20--60% cases of EMPD and signifies poor prognosis often due to deep dermal invasion or metastatic disease \[[@CR21]\]. The p63 expression in the epidermis and sebaceous glands is useful to differentiate pagetoid bowels disease from EMPD \[[@CR22]\]. Our PPD patient presented both HER and p63 negative confirming no internal malignancies or metastasis.

The primary PPD diagnosis must be established using histological examination showing the presence of Paget cells and different histological markers to establish primary cutaneous origin or secondary internal malignancy.

A wide range of PPD treatment modalities have been previously reported, including surgery \[[@CR23], [@CR24]\], abdominoperineal resection \[[@CR25]\], radiotherapy \[[@CR26]\], and chemo-radiotherapy \[[@CR27]\]. Few authors have suggested nonsurgical treatment first. Kobayashi et al. \[[@CR28]\] reported the effect of intralesional interferon. Our case was treated using Imiquimod 5% cream and complete healing without recurrence of PPD was observed. One previous report showed similar results in a long-lasting PPD patient without deep gastrointestinal neoplasia \[[@CR29]\]. Recently, another report described the primary local treatment of PPD with Imiquimod 5% cream over a 16-week period initially resulting in remission prior to lymph node spread at 18 months \[[@CR19]\].

The present case corresponds to stage I according to Shutze and Gleysteen classification \[[@CR30]\]. Recommendation for stages I and II is a wide local excision \[[@CR13]\]; however, Imiquimod was successfully an alternative treatment in our case. Long-term follow-up is required to exclude the recurrence of the disease and development of associated tumors.

In conclusion, this study reports clinical characteristics of this rare disease in a Brazilian patient and suggests the use of a nonsurgical treatment for early-stage PPD.
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